Results 141 to 150 of about 1,419,720 (263)

Cardiovascular Outcomes of Insulin Degludec Versus Insulin Glargine in Trial‐Eligible and Ineligible Populations: A DEVOTE‐Inspired Target Trial Emulation Using the Swedish National Diabetes Register

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims To compare cardiovascular outcomes associated with the initiation of insulin degludec versus insulin glargine using a target trial emulation approach in nationwide real‐world data. Materials and Methods We conducted a nationwide observational cohort study using Swedish health registers, including the National Diabetes Register ...
Thomas Nyström, Jens Michelsen, Henrik Imberg, Sara Hallström, Viktor Tasselius, Anna Norhammar, Max Petzold, Julia K. Mader, Pratik Choudhary, Manal K. Elzalabany, Jonathan Valabhji, Shivani Misra, Safoora Gharibzadeh, Puriya Daniel Würtz Yazdanfard, Kathrine Kold Sørensen, Christian Torp‐Pedersen, Marcus Lind   +16 more
wiley   +1 more source

Dose–Exposure–Response Analysis of Finerenone on Serum Potassium and Cardiovascular Outcomes Among Patients With Heart Failure: Insights From FINEARTS‐HF

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Background Finerenone reduces the risk of heart failure and cardiovascular (CV) death among patients with heart failure with mildly reduced or preserved ejection fraction (HFmrEF/HFpEF). Whether the effects of finerenone to reduce CV risk are dose/exposure dependent is not clear.
Thomas Eissing, Finnian R. Mc Causland, Muthiah Vaduganathan, Sebastiaan C. Goulooze, Eleonora Marostica, Jan Berkhout, Paul van den Berg, Nelleke Snelder, Dirk Garmann, Joerg Lippert, Meike Brinker, Brian L. Claggett, John J. V. McMurray, Scott D. Solomon   +13 more
wiley   +1 more source

Mineralocorticoid receptor antagonists in the treatment of patients with chronic heart failure. Positions in 2015

Терапевтический архив, 2015
Mineralocorticoid receptor antagonists (MCRA) are part of standard medical therapy for heart failure (HF). The clinical efficacy of MCRA in patients with systolic HF has been proven by randomized clinical trials.
Yu F Osmolovskaya, I V Zhirov, S N Tereshchenko   +2 more
doaj  

At the heart of home‐based care: multidisciplinary heart failure management in a quaternary centre's community programmes

Internal Medicine Journal, EarlyView.
Abstract Background Heart failure (HF) is a frequent cause of hospital admissions, carrying a high risk of hospital readmission and mortality. Alfred Health General Medicine Hospital in the Home (GM‐HITH) and Hospital Admission Risk Program (HARP) offer multidisciplinary HF care to multimorbid patients in bed‐substitution and non‐admitted community ...
Elana Forbes, Ingrid Hopper, Cathy Corbett, Felice Borghmans, Emma O'Donnell, Ana Slavnic, Genevieve Harvey, Elizabeth Rochford, Archana Thayaparan   +8 more
wiley   +1 more source

Semaglutide in type 2 diabetes and chronic kidney disease in Australia: practical clinical considerations from a multidisciplinary panel

Internal Medicine Journal, EarlyView.
Abstract Chronic kidney disease (CKD) and cardiovascular disease (CVD) are major causes of morbidity and mortality in people with type 2 diabetes (T2D). Contemporary CKD guidelines increasingly support incorporation of glucagon‐like peptide‐1 receptor agonists (GLP‐1RAs) as an additional pillar of cardiorenal therapy alongside renin–angiotensin ...
Eugenia Pedagogos, Roger Chen, Adam Nelson, Sunil Badve, Roy Rasalam, Richard MacIsaac   +5 more
wiley   +1 more source

Pulmonary Vein Isolation Alone Versus Adjunctive Ablation for Paroxysmal Atrial Fibrillation

Journal of Cardiovascular Electrophysiology, EarlyView.
Clinical Outcomes of Pulmonary Vein Isolation Alone Versus Additional Lesion Sets in Paroxysmal Atrial Fibrillation ABSTRACT Background Pulmonary vein isolation (PVI) is the standard ablation strategy for paroxysmal atrial fibrillation (PAF). Despite guideline recommendations favoring PVI alone in PAF, some operators routinely perform extra pulmonary ...
Michel Abou Khalil, Christian M. Massad, Eli Tsakiris, William Herbst, Maximilian Moersdorf, Mohammad Montaser Atasi, Yara Menassa, Alex El Darzi, Carlo El Khoury, Ghassan Bidaoui, Hadi Younes, Yishi Jia, Rodolfo Montiel, Amitabh Pandey, Han Feng, Qussay Marashly, Nassir F. Marrouche, Omar Kreidieh   +17 more
wiley   +1 more source

Clinical Properties and Non-Clinical Testing of Mineralocorticoid Receptor Antagonists in In Vitro Cell Models

Mineralocorticoid receptor antagonists (MRAs) are one of the renin–angiotensin–aldosterone system inhibitors widely used in clinical practice.
Luka Varda, Robert Ekart, Bevc, Sebastjan, Ekart, Robert, Uroš Maver, Maver, Uroš, Lainščak, Mitja, Sebastjan Bevc, Varda, Luka, Mitja Lainscak   +9 more
core   +1 more source

Temporal Association Between Intrathoracic Impedance and Tachyarrhythmia Occurrence

Journal of Cardiovascular Electrophysiology, EarlyView.
A decrease in intrathoracic impedance is temporally associated with subsequent AF occurrence and, at the episode level, with a shorter time to VT. These findings suggest that daily intrathoracic impedance may provide information on short‐term changes preceding tachyarrhythmia occurrence.
Monika Butkuvienė, Andrius Petrėnas, Andrius Sološenko, Anneli Olsson, Rasmus Borgquist, Pyotr G. Platonov   +5 more
wiley   +1 more source

Aldosterone and aldosterone receptor antagonists in patients with chronic heart failure

, 2011
Jean M Nappi, Adam SiegClinical Pharmacy and Outcome Sciences, South Carolina College of Pharmacy, Medical University of South Carolina Campus, Charleston, SC, USAAbstract: Aldosterone is a mineralocorticoid hormone synthesized by the adrenal glands that
Nappi J, Sieg
core  

Linagliptin increases the expression of LRP2 independent of Nrf2 in streptozotocin‐induced diabetic mice

Journal of Diabetes Investigation, EarlyView.
ABSTRACT Aims/Introduction Oxidative stress is thought to play a role in the onset and progression of diabetic nephropathy (DN). Nuclear factor erythroid‐related factor 2 (Nrf2) is a master regulator of antioxidant and detoxification pathways and provides cellular protection against oxidative stress.
Suratsawadee Promsuwan, Yumi Takiyama, Takao Takiyama, Yuri Takiyama, Hiroya Kitsunai, Hiroshi Nomoto   +5 more
wiley   +1 more source